Answers are grounded in this paper and cite their sources.
Photodynamic therapy (PDT) is significantly constrained in hypoxic tumor microenvironments (TMEs) because conventional Type II photosensitization depends strongly on molecular oxygen for efficient singlet oxygen generation. This limitation has stimulated increasing interest in Type I photosensitizers, which initiate photochemical reactions through electron or hydrogen transfer and can retain reactive oxygen species (ROS)‐generating activity under reduced oxygen availability. In some Type I PDT systems, additional oxygen‐regulating processes can further alleviate local hypoxia, thereby sustaining O 2 − ‐dependent downstream ROS generation while contributing to the modulation of the TME. These properties also support combination strategies with photothermal therapy, immunotherapy, or chemotherapy to enhance therapeutic outcomes. This review systematically examines Type I photosensitizers within a framework linking molecular design, photophysical and photochemical properties, mechanistic pathways, and biomedical applications. Their classification, structure–property relationships, and mechanisms of action are critically examined, with particular emphasis on recent advances in hypoxia‐tolerant PDT, multimodal combination therapy, and imaging‐guided theranostics. Finally, the remaining challenges and future directions are discussed with the aim of facilitating the translation of Type I photosensitizers from fundamental research toward clinical cancer theranostics.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: